Screener
Immunome IMNM Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Immunome’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344636
FAQ
- What is Immunome's restricted cash?
- Immunome (IMNM) reported restricted cash of $210K in Q2 2026.
- How has Immunome's restricted cash changed year-over-year?
- Immunome's restricted cash decreased by 0.0% year-over-year, from $210K to $210K.
- What is the long-term trend for Immunome's restricted cash?
- Over 5 years (2020 to 2025), Immunome's restricted cash has grown at a 16.0% compound annual growth rate (CAGR), from $100K to $210K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Immunome's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude